PMVP
What one share of Pmv Pharmaceuticals holds
Pharmaceutical Preparations
We are a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 is a well-defined tumor suppressor protein known as the “guardian of the genome,” and normal, or wild-type, p53 has the ability to eliminate cancer cells.
Pmv Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.41 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.34 |
| Cash and investments | $1.49 |
| Book value | $1.34 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | — | −$5.82 | $0.15 | −$5.19 | — | −$15.32 |
| 2019 | — | −$8.35 | $0.04 | −$7.31 | — | −$23.14 |
| 2020 | — | −$2.40 | $0.01 | −$2.29 | — | — |
| 2021 | — | −$1.28 | $0.03 | −$1.06 | — | $6.79 |
| 2022 | — | −$1.61 | $0.18 | −$1.57 | — | $5.38 |
| 2023 | — | −$1.44 | $0.02 | −$1.18 | — | $4.39 |
| 2024 | — | −$1.14 | $0.01 | −$1.01 | — | $3.39 |
| 2025 | — | −$1.48 | $0.00 | −$1.40 | — | $1.96 |